Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia

Bosutinib (SKI-606) is an oral, dual Src/Abl tyrosine kinase inhibitor (TKI) approved for treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) that is resistant or intolerant to prior TKI therapy or for whom other TKIs are not appropriate choices. The obje...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoury, H J, Gambacorti-Passerini, C, Brümmendorf, T H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888919/
https://www.ncbi.nlm.nih.gov/pubmed/29385394
http://dx.doi.org/10.1093/annonc/mdy019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888919/
https://www.ncbi.nlm.nih.gov/pubmed/29385394
http://dx.doi.org/10.1093/annonc/mdy019

Ejemplares similares